
Ironwood Pharmaceuticals, Inc.: shareholders and insiders
Price
$4.70
November 20, 2026Market cap $766M
What Ploutos Investor adds for Ironwood Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 21, 2025 to Nov 18, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$23M
8 people
From Nov 21, 2025 to Nov 21, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan4%
- The rest96%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 21, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $23M by 8 people
- 2025: no buys, no sales
- 2026: no buys, sold $23M by 8 people
- Nov 16, 2026Tammi L GaskinsChief Commercial OfficerKind
- Sep 15, 2026Alexander J DennerDirectorKind
- Jul 20, 2026Jeffrey SilberSVP, CMO, Head-Res&DrugKind
- Jul 7, 2026Ronald SilverPFO & PAOKind10b5-1
- Jun 16, 2026Jay ShepardDirectorKind
- Jun 16, 2026Marla L KesslerDirectorKind
- Jun 16, 2026Mark G CurrieDirectorKind
- Jun 16, 2026Jon R DuaneDirectorKind
- Jun 16, 2026Alexander J DennerDirectorKind
- Jun 16, 2026Julie McHughDirectorKind10b5-1
- Jun 16, 2026Julie McHughDirectorKind10b5-1
- Jun 16, 2026Catherine MoukheibirDirectorKind
- Jun 15, 2026Alexander J DennerDirectorKind
- Mar 17, 2026Alexander J DennerKind
- Mar 17, 2026Alexander J DennerKind
- Feb 24, 2026Ronald SilverPrincipal Accounting OfficerKind
- Feb 24, 2026Thomas A MCCOURTChief Executive OfficerKind
- Feb 24, 2026Tammi L GaskinsChief Commercial OfficerKind
- Feb 24, 2026Michael ShetzlineSVP, CMO, Head-Res&DrugKind
- Feb 24, 2026Minardo JohnChief Legal OfficerKind
- Feb 24, 2026Gregory S. MartiniChief Financial OfficerKind
- Feb 23, 2026Ronald SilverPrincipal Accounting OfficerKind
- Feb 23, 2026Thomas A MCCOURTChief Executive OfficerKind
- Feb 23, 2026Tammi L GaskinsChief Commercial OfficerKind
- Feb 23, 2026Michael ShetzlineSVP, CMO, Head-Res&DrugKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | Tammi L GaskinsChief Commercial Officer | 5,919 | $4.81 | $28.5K | Form 4 | |
| Sep 15, 2026 | Alexander J DennerDirector | 3,694 | – | – | Form 4 | |
| Jul 20, 2026 | Jeffrey SilberSVP, CMO, Head-Res&Drug | 137.0K | – | – | Form 4 | |
| Jul 7, 2026 | Ronald SilverPFO & PAO | 10b5-1 | 127.9K | $4.52 | $578.1K | Form 4 |
| Jun 16, 2026 | Jay ShepardDirector | 63.5K | – | – | Form 4 | |
| Jun 16, 2026 | Marla L KesslerDirector | 63.5K | – | – | Form 4 | |
| Jun 16, 2026 | Mark G CurrieDirector | 63.5K | – | – | Form 4 | |
| Jun 16, 2026 | Jon R DuaneDirector | 63.5K | – | – | Form 4 | |
| Jun 16, 2026 | Alexander J DennerDirector | 63.5K | – | – | Form 4 | |
| Jun 16, 2026 | Julie McHughDirector | 10b5-1 | 63.5K | – | – | Form 4 |
| Jun 16, 2026 | Julie McHughDirector | 10b5-1 | 21.6K | $3.73 | $80.5K | Form 4 |
| Jun 16, 2026 | Catherine MoukheibirDirector | 63.5K | – | – | Form 4 | |
| Jun 15, 2026 | Alexander J DennerDirector | 4,065 | – | – | Form 4 | |
| Mar 17, 2026 | Alexander J Denner | 6.73M | $3.05 | $21M | Form 4 | |
| Mar 17, 2026 | Alexander J Denner | 5,800 | $3.31 | $19.2K | Form 4 | |
| Feb 24, 2026 | Ronald SilverPrincipal Accounting Officer | 12.6K | $3.66 | $46.2K | Form 4 | |
| Feb 24, 2026 | Thomas A MCCOURTChief Executive Officer | 103.5K | $3.66 | $378.9K | Form 4 | |
| Feb 24, 2026 | Tammi L GaskinsChief Commercial Officer | 11.2K | $3.66 | $41.1K | Form 4 | |
| Feb 24, 2026 | Michael ShetzlineSVP, CMO, Head-Res&Drug | 17.0K | $3.66 | $62.3K | Form 4 | |
| Feb 24, 2026 | Minardo JohnChief Legal Officer | 19.1K | $3.66 | $69.7K | Form 4 | |
| Feb 24, 2026 | Gregory S. MartiniChief Financial Officer | 11.5K | $3.66 | $41.9K | Form 4 | |
| Feb 23, 2026 | Ronald SilverPrincipal Accounting Officer | 11.6K | $3.81 | $44.0K | Form 4 | |
| Feb 23, 2026 | Thomas A MCCOURTChief Executive Officer | 94.8K | $3.81 | $361.0K | Form 4 | |
| Feb 23, 2026 | Tammi L GaskinsChief Commercial Officer | 10.3K | $3.81 | $39.2K | Form 4 | |
| Feb 23, 2026 | Michael ShetzlineSVP, CMO, Head-Res&Drug | 15.6K | $3.81 | $59.3K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 17, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by IRWD's officers and directors from 2010 up to November 20, 2025, 16 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 11 more, back to 2010
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Armistice Capital, LLCwith 1 more personClass A common stock, $0.001 par valueShare of class8.43%
- BlackRock, Inc.Class A StockShare of class8.10%
- Sarissa Capital Management LPwith 1 more personClass A Common Stock, $0.001 par valueShare of class5.80%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Armistice Capital, LLCwith 1 more personClass A common stock, $0.001 par value | 8.43% | 13.93M | Aug 14, 20266 filings since Feb 14, 2025 | 13G/A | |
| BlackRock, Inc.Class A Stock | 8.10% | 13.37M | Jul 28, 20262 filings since Mar 7, 2025 | 13G/A | |
| Sarissa Capital Management LPwith 1 more personClass A Common Stock, $0.001 par value | 5.80% | 9.44M | Mar 19, 2026 | 13D/A |
Fell to 5% or less (6)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Renaissance TechnologiesIn the quarter+0.6%
- AQR CapitalIn the quarter-9.9%
- Citadel Advisors (Griffin)In the quarter-40%
- Millennium Mgmt (Englander)In the quarter
- D.E. ShawIn the quarter-47%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Renaissance Technologies | 8.04M | +0.6% | $32M | 0.04% |
| AQR Capital | 5.82M | -9.9% | $23M | 0.01% |
| Citadel Advisors (Griffin) | 299.7K | -40% | $1.2M | 0.00% |
| Millennium Mgmt (Englander) | 80.8K | $300.0K | 0.00% | |
| D.E. Shaw | 65.3K | -47% | $300.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 9.74% of its shares outstanding were held short, +2.1% since the report before.
- Shares held short
- 15.89M
- 9.74%
- Since the report before15.57M on Sep 30, 2026
- +2.1%
- 8.0
- 1.99M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 83%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 17.39M
- Nov 15, 2023: Shares held short 17.15M
- Nov 30, 2023: Shares held short 16.62M
- Dec 15, 2023: Shares held short 17.00M
- Dec 29, 2023: Shares held short 15.76M
- Jan 12, 2024: Shares held short 16.08M
- Jan 31, 2024: Shares held short 14.46M
- Feb 15, 2024: Shares held short 15.60M
- Feb 29, 2024: Shares held short 15.51M
- Mar 15, 2024: Shares held short 18.77M
- Mar 28, 2024: Shares held short 21.95M
- Apr 15, 2024: Shares held short 21.16M
- Apr 30, 2024: Shares held short 20.08M
- May 15, 2024: Shares held short 22.48M
- May 31, 2024: Shares held short 22.66M
- Jun 14, 2024: Shares held short 20.22M
- Jun 28, 2024: Shares held short 18.07M
- Jul 15, 2024: Shares held short 16.85M
- Jul 31, 2024: Shares held short 15.80M
- Aug 15, 2024: Shares held short 14.00M
- Aug 30, 2024: Shares held short 13.60M
- Sep 13, 2024: Shares held short 11.61M
- Sep 30, 2024: Shares held short 11.79M
- Oct 15, 2024: Shares held short 11.93M
- Oct 31, 2024: Shares held short 10.96M
- Nov 15, 2024: Shares held short 8.57M
- Nov 29, 2024: Shares held short 11.22M
- Dec 13, 2024: Shares held short 12.08M
- Dec 31, 2024: Shares held short 9.22M
- Jan 15, 2025: Shares held short 9.45M
- Jan 31, 2025: Shares held short 10.75M
- Feb 14, 2025: Shares held short 10.70M
- Feb 28, 2025: Shares held short 12.05M
- Mar 14, 2025: Shares held short 16.25M
- Mar 31, 2025: Shares held short 11.25M
- Apr 15, 2025: Shares held short 11.64M
- Apr 30, 2025: Shares held short 8.80M
- May 15, 2025: Shares held short 8.47M
- May 30, 2025: Shares held short 8.23M
- Jun 13, 2025: Shares held short 7.65M
- Jun 30, 2025: Shares held short 7.48M
- Jul 15, 2025: Shares held short 6.53M
- Jul 31, 2025: Shares held short 5.38M
- Aug 15, 2025: Shares held short 6.07M
- Aug 29, 2025: Shares held short 6.06M
- Sep 15, 2025: Shares held short 5.71M
- Sep 30, 2025: Shares held short 5.17M
- Oct 15, 2025: Shares held short 4.70M
- Oct 31, 2025: Shares held short 4.76M
- Nov 14, 2025: Shares held short 7.15M
- Nov 28, 2025: Shares held short 7.46M
- Dec 15, 2025: Shares held short 7.33M
- Dec 31, 2025: Shares held short 8.15M
- Jan 15, 2026: Shares held short 9.01M
- Jan 30, 2026: Shares held short 9.46M
- Feb 13, 2026: Shares held short 11.16M
- Feb 27, 2026: Shares held short 12.92M
- Mar 13, 2026: Shares held short 13.70M
- Mar 31, 2026: Shares held short 17.90M
- Apr 15, 2026: Shares held short 18.19M
- Apr 30, 2026: Shares held short 17.27M
- May 15, 2026: Shares held short 17.33M
- May 29, 2026: Shares held short 15.02M
- Jun 15, 2026: Shares held short 15.90M
- Jun 30, 2026: Shares held short 16.23M
- Jul 15, 2026: Shares held short 17.19M
- Jul 31, 2026: Shares held short 16.54M
- Aug 14, 2026: Shares held short 18.07M
- Aug 31, 2026: Shares held short 17.65M
- Sep 15, 2026: Shares held short 18.73M
- Sep 30, 2026: Shares held short 15.57M
- Oct 15, 2026: Shares held short 15.89M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading37.2% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 37.2% of the shares in the reported trades were short sales, against 55.4% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 37.2%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 55.4%
- Change
- -18.2 pts
- Short sales a dayon average, of 1.17M shares
- 434.6K
- More than atof 3,674 US-listed companies, same days
- 14%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 49.5%
- Oct 15, 2026: Short sales 55.4%
- Oct 16, 2026: Short sales 64%
- Oct 19, 2026: Short sales 42.9%
- Oct 20, 2026: Short sales 53%
- Oct 21, 2026: Short sales 61.8%
- Oct 22, 2026: Short sales 53.5%
- Oct 23, 2026: Short sales 58.8%
- Oct 26, 2026: Short sales 62%
- Oct 27, 2026: Short sales 33.1%
- Oct 28, 2026: Short sales 61.8%
- Oct 29, 2026: Short sales 40.3%
- Oct 30, 2026: Short sales 65.5%
- Nov 2, 2026: Short sales 68.2%
- Nov 3, 2026: Short sales 31.4%
- Nov 4, 2026: Short sales 51.1%
- Nov 5, 2026: Short sales 31.4%
- Nov 6, 2026: Short sales 22.2%
- Nov 9, 2026: Short sales 38.6%
- Nov 10, 2026: Short sales 35.6%
- Nov 11, 2026: Short sales 28.2%
- Nov 12, 2026: Short sales 27.2%
- Nov 13, 2026: Short sales 35.2%
- Nov 16, 2026: Short sales 44.4%
- Nov 17, 2026: Short sales 49%
- Nov 18, 2026: Short sales 44%
- Nov 19, 2026: Short sales 49.7%
- Nov 20, 2026: Short sales 43.1%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Mark G CurrieDirectorDirectly676.9K
- Michael ShetzlineSVP, CMO, Head-Res&DrugDirectly521.4K
- Tammi L GaskinsChief Commercial OfficerDirectly344.4K
- Alexander J DennerDirectorDirectly327.5K
- Ronald SilverPFO & PAODirectly313.7K
- Jon R DuaneDirectorDirectly253.8K
- Julie McHughDirectorDirectly250.7K
- Jay ShepardDirectorDirectly235.0K
- Marla L KesslerDirectorDirectly229.4K
- Catherine MoukheibirDirectorDirectly181.4K
- Jeffrey SilberSVP, CMO, Head-Res&DrugDirectly137.0K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Mark G CurrieDirector | 676.9K | – | Jun 16, 2026 | Form 4 |
| Michael ShetzlineSVP, CMO, Head-Res&Drug | 521.4K | – | Feb 24, 2026 | Form 4 |
| Tammi L GaskinsChief Commercial Officer | 344.4K | – | Nov 16, 2026 | Form 4 |
| Alexander J DennerDirector | 327.5K | – | Sep 15, 2026 | Form 4 |
| Ronald SilverPFO & PAO | 313.7K | – | Jul 7, 2026 | Form 4 |
| Jon R DuaneDirector | 253.8K | – | Jun 16, 2026 | Form 4 |
| Julie McHughDirector | 250.7K | – | Jun 16, 2026 | Form 4 |
| Jay ShepardDirector | 235.0K | – | Jun 16, 2026 | Form 4 |
| Marla L KesslerDirector | 229.4K | – | Jun 16, 2026 | Form 4 |
| Catherine MoukheibirDirector | 181.4K | – | Jun 16, 2026 | Form 4 |
| Jeffrey SilberSVP, CMO, Head-Res&Drug | 137.0K | – | Jul 20, 2026 | Form 4 |
A lower bound: it counts only the 11 officers and directors with a market trade since Nov 22, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.22%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.16%
- IWCiShares Micro-Cap ETFWeight in the fund0.15%
- CALFPacer US Small Cap Cash Cows 100 ETFWeight in the fund0.12%
- FNDASchwab Fundamental U.S. Small Company ETFWeight in the fund0.08%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.05%
- IBBiShares Biotechnology ETFWeight in the fund0.05%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.04%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.02%
- IWMiShares Russell 2000 ETFWeight in the fund0.02%
21 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 166
- Q4 2025: Managers 199
- Q1 2026: Managers 228
- Q2 2026: Managers 212
Institutional investors by quarter
The fund managers holding IRWD, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 212 managers held 161M shares, worth $676M. During the quarter 24 opened a position, 40 closed one, 70 added and 83 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+33%
- Armistice CapitalIn the quarter-7.3%
- Sarissa Capital ManagementIn the quarter
- State StreetIn the quarter+18%
- Bank of AmericaIn the quarter
- Renaissance TechnologiesIn the quarter-0.8%
- Vanguard Capital ManagementIn the quarter+8.4%
- AQR CapitalIn the quarter-14%
- Acadian Asset ManagementIn the quarter-11%
- Vanguard Portfolio ManagementIn the quarter-17%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 17.79M | +33% | $75M |
| Armistice Capital | 13.93M | -7.3% | $59M |
| Sarissa Capital Management | 9.19M | $39M | |
| State Street | 8.81M | +18% | $37M |
| Bank of America | 8.68M | $37M | |
| Renaissance Technologies | 7.99M | -0.8% | $34M |
| Vanguard Capital Management | 6.61M | +8.4% | $28M |
| AQR Capital | 6.47M | -14% | $27M |
| Acadian Asset Management | 5.85M | -11% | $25M |
| Vanguard Portfolio Management | 5.51M | -17% | $23M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Ironwood Pharmaceuticals's filings show?
Who buys and sells is one part of Ironwood Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have IRWD's insiders bought or sold?
From Jun 17, 2026 to Nov 18, 2026 Ironwood Pharmaceuticals's insiders bought 0 and sold $687.0K of shares on the market. 96% of the sales were under set 10b5-1 plans.
Which well-known managers hold IRWD?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $32M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.